Table 2.

Summary estimates from three meta-analyses on residential D/M and health.

	Subject groups	OR (95% CI)
		Fisk et al. 2007a	Fisk et al. 2010a	Antova et al. 2008b
Upper respiratory tract symptoms	All	1.70 (1.44–2.00)
Cough	All	1.67 (1.49–1.86)
	Adults	1.52 (1.18–1.96)		1.30 (1.22–1.39)c
	Children	1.75 (1.56–1.96)		1.50 (1.31–1.73)d
Wheeze	All	1.50 (1.38–1.64)
	Adults	1.39 (1.04–1.85)		1.43 (1.36–1.49)e
	Children	1.53 (1.39–1.68)		1.49 (1.28–1.74)f
Current asthma	All	1.56 (1.30–1.86)
Ever-diagnosed asthma	All	1.37 (1.23–1.53)
	Children			1.35 (1.20–1.51)
Asthma development	All	1.34 (0.86–2.10)
Bronchitis	All		1.45 (1.32–1.59)
	Children			1.38 (1.28–1.47)
Respiratory infections	All		1.44 (1.31–1.59)
	Adults		1.49 (1.14–1.95)
	Children		1.48 (1.33–1.65)
Respiratory infectionsg	All		1.50 (1.32–1.70)
Sensitivity to inhaled antigens	Children			1.33 (1.23–1.44)
Hay fever	Children			1.35 (1.18–1.53)

^aBased on all eligible published studies at the time, ranging from 4 to 22 studies for each outcome; all risk factors of visible mold, visible water damage, mold odor, and various combinations of these were included together.

^bBased on a total of 12 studies in 12 countries, including over 57,000 children: 10 studies of any visible mold, 1 study of any visible mold in last 12 months, and 1 study of any visible mold in child’s bedroom.

^cNocturnal dry cough.

^dMorning cough.

^eWheeze in the last 12 months.

^fWoken by wheeze.

^gIncluding lower respiratory infections, tonsillitis, sinusitis, otitis, and pharyngitis, but excluding nonspecific upper respiratory infections.